BioPharmSignal logoBioPharmSignal

Biotech News

Molecular Partners Reports Q3 2026 Financial Results, Deepens Focus on Targeted Radiotherapy

Molecular Partners (MOLN)Molecular PartnersEarnings

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX, NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of medicines known as DARPin therapeutics, (“Molecular Partners” or the “Company”), today announced corporate highlights and unaudited financial results for the third quarter of 2026, as well as a deepened focus on radiopharmaceuticals and streamlining of its resources.

Related news

IMCRImmunocore Holdings plc2026-11-06 14:00 EST

Immunocore reports third quarter financial results and provides a business update

ELVNEnliven Therapeutics2026-11-05 21:05 EST

Enliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business Update

COGTCogent Biosciences2026-11-05 21:02 EST

Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2026 Financial Results

FATEFate Therapeutics2026-11-05 12:00 EST

Fate Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates

LYELLyell Immunopharma2026-11-04 21:05 EST

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2026

RVMDRevolution Medicines2026-11-04 21:02 EST

Revolution Medicines Reports Third Quarter 2026 Financial Results and Update on Corporate Progress

URGNUroGen Pharma2026-11-04 13:00 EST

UroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and Highlights

KURAKura Oncology2026-11-03 11:58 EST

Kura Oncology to Report Third Quarter Financial Results on November 10

IDYAIDEAYA Biosciences2026-11-03 11:00 EST

IDEAYA Biosciences Reports Financial Results for the Third Quarter 2026 and Provides a Business Update

EXELExelixis2026-10-29 20:05 EST

Exelixis Announces Third Quarter 2026 Financial Results and Provides Corporate Update

View all latest news

Molecular Partners

DARPin Therapeutics Platform Molecular Partners develops multi-specific protein medicines based on Designed Ankyrin Repeat Proteins, compact binding molecules that can be engineered for high affinity and modularity. Radio-DARPins The company is attaching therapeutic radioisotopes to DARPins to deliver radiation selectively to tumor...

Recent company news

MOLNMolecular Partners2026-10-29 06:00 EST

Molecular Partners Reports Q3 2026 Financial Results, Deepens Focus on Targeted Radiotherapy

MOLNMolecular Partners2026-10-22 05:00 EST

Molecular Partners Nominates MP0730 as Next Candidate in Expanding Pipeline of Radiotherapeutics, Targeting CD70

MOLNMolecular Partners2026-08-25 19:02 EST

Molecular Partners gibt Finanzergebnisse für das erste Halbjahr 2026 und wichtige Unternehmensentwicklungen bekannt: DLL3-Radiotherapie-Kandidat MP0712 erreicht in der Phase-1/2a-Studie die nächsthöhere Dosisstufe

MOLNMolecular Partners2026-08-25 05:00 EST

Molecular Partners Reports H1 2026 Financial Results and Corporate Highlights: DLL3 Radiotherapy MP0712 Successfully Advancing to Higher Dose Level in Phase 1/2a Study

MOLNMolecular Partners2026-07-16 05:00 EST

Molecular Partners Announces Clinical Progress in Phase 2 TACTIC Combination Trial of MP0317 for Patients with Cholangiocarcinoma

Stock data

Close
3.22 USD
Market cap
147.04M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States